THE ASSOCIATION OF DYSLIPIDEMIA WITH INTRAPERITONEAL INFLAMMATION AND PERITONEAL DIALYSIS TECHNIQUE SURVIVAL
Abstract
The aim of the study was to determine the relationship between the dyslipidemia, intraperitoneal inflammation and peritoneal dialysis (PD) survival.
Patients and methods. A total of 40patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis (PD) have been included in a prospective, observational study (average age was 49.3 ± 12.7). All patients were determined the blood lipid spectrum and IL-10, TNF-a, MCP-1 levels in peritoneal dialysis effluent (PDE). PD adequacy indicators evaluated by determining the concentration of urea and creatinine in plasma, urine and dialysate, calculated weekly creatinine clearance (CrCl), dialysis (Kt/ Vd), renal (Kt/ Vr) and total weekly urea clearance (Kt/ V).
Results. Dyslipidemia defined as increase of atherogenic lipoprotein fractions and inhibition ofHDL cholesterol was identified in 70% of the PD-patients. LDL cholesterol level and, accordingly, an atherogenic index (AI) were significantly dependent on the duration of PD treatment (R2 = 2.18 ± 0.15 (95% CI 1.87, 2.5), p < 0,0001 and R2 = 2.77 ± 0.27(95% CI 2.2, 3.3), p < 0,0001). The blood levels of total cholesterol, LDL-C and TG in the patients with diabetes were significantly higher compared with the diabetes-free patients (p = 0.007, p = 0.001 andp = 0.02, respectively).
Reducing the HDL cholesterol level was associated with high intraperitoneal production of pro-inflammatory mediators TNF-a (r = - 0.53;p = 0.001) and anti-inflammatory IL-10 (r = - 0.783;p <0.0001), whereas hypertriglyceridemia and high VLDL cholesterol are associated with an increase of MCP-1 (r = 0.6;p = 0.0003 and r = 0.55;p = 0.002, respectively).
The Cox proportional hazards regression analysis demonstrated the significant effect of VLDL cholesterol, LDL cholesterol and AI on the survival of PD technique survival (x2 = 24.8; p < 0.0001). The results of the Kaplan–Meier analysis and log-rank test also identified that there was a significant difference in the cumulative technical survival rate between the patients with AI level < 3.5 and > 3.5 (log-rank test: x2 = 19.8, P = 0.001.
Conclusions. Our results can be considered dyslipidemia in PD-patients not only as a traditional risk factor for CVD, but also as a predictor of chronic intraperitoneal inflammation and decrease of PD technical survival.
Downloads
References
Ama Moor V. J. Assessment of the 10-year risk of cardiovascular disease among a group of patients on maintenance hemodialysis: A cross-sectional study
from Cameroon (Electronic resource) / Ama Moor V. J., Nansseu J. R. N., Azingni D. B. T., Kaze F. F. // JRSM Cardiovascular Disease – 2017. – Mode of access : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406155/
Association of inflammatory cytokines with mortality in peritoneal dialysis patients (Electronic resource) / Yao-Lung Liu, Jiung-Hsiun Liu, I-Kuan Wang // BioMedicine 2017. – V. 7, No 1 – Mode of access : https://www.ncbi.nlm.nih.gov/pmc/ar- ticles/PMC5439334/
Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients / Chang T., Streja E., Soohoo M., Kim T. W. // Clin J Am Soc Nephrol. - 2017. - V. 3; 12 (4). - P. 591-602.
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths / Lewington S., Whitlock G., Clarke R., [et al.] // Lancet. - 2007. - V. - 370. - P.1829-1839.
Chen H. Y. Association between dyslipidemia and residual renal function in patients on chronic peritoneal dialysis / Chen H. Y., Kao T. W., Huang J. W., Tsai T. J., Wu K. D. // Clin. Nephrol. - 2008. - V. 70 (3). - P. 233-239.
Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients / Harmankaya O., Akalin N., Akay H., [et al.] // Clinics. - 2015. - V. - 70 (9). - P. 601-605.
Dialysis Modalities and HDL Composition and Function / Holzer M., Schilcher G., Curcic S., [et al.] // Journal of the American Society of Nephrology : JASN. - 2015. - V. - 26 (9). - P. 2267-2276.
Different effect of hypercholesterolemia on mor tality in hemodialysis patients based on coronary artery disease or myocardial infarction (Electronic resource) / Lin Y-C., Lin Y-C., Chen H-H., [et al.] // Lipids in Health and Disease. - 2016. - V. - 15 (211). - Mode of access : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143465/
Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis / Babazono T., Nakamoto H., Kasai K., [et al.] // J Nephrol. - 2007. - V. - 27 (4). - P. 409-415.
Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients / Moradi H., Streja E., Kashyap M. L., Vaziri N. D., [et al.] // Nephrology Dialysis Transplantation. - 2014. - V. - 29 (8). - P. 15541562.
Galkina E. Immune and Inflammatory Mechanisms of Atherosclerosis / Galkina E., Ley K. // Annual review of immunology. - 2009. - V. - 27. - P. 165-197.
HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction / Zewinger S., Speer T., Kleber M. E., [et al.] // Journal of the American Society of Nephrology : JASN. - 2014 . - V. - 25 (5). - P. 1073-1082.
HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients / Silbernagel G., Genser B., Drechsler C., [et al.] // Journal of the American Society of Nephrology : JASN. - 2015. - V. 26 (2). - P. 484-492.
HDL in innate and adaptive immunity / A. Catapano, A. Pirillo, Fabrizia Bonacina, [et al.] // Cardiovasc Res. - 2014. - V. 103 (3). - P. 372383.
KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease // Kidney International Supplements. - 2013. - V. 3. - P. 271-279.
Kusters P. J. Cytokines and Immune Responses in Murine Atherosclerosis / Kusters P. J., Lutgens E. // Methods Mol Biol. - 2015. - V. - 1339. - P. 17-40.
Mikolasevic I. Dyslipidemia in patients with chronic kidney disease: etiology and management / Mikolasevic I., Zutelija M., Mavrinac V., Orlic
L. // International Journal of Nephrology and Renovascular Disease. – 2017. – V. – 10. – P. 35-45.
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins (Electronic resource) / Vanholder R., Florens N , Calzada C., [et al.] // ed Toxins. – 2016. – V. 8 (12) : 376. – Mode of access : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198570/
Norata G. D. Emerging role of high density lipoproteins as a player in the immune system / Norata G. D., Pirillo A., Ammirati E., Catapano A. L. // Atherosclerosis. – 2012. – V. – 220. – P. 11–21.
Pennell P. Managing metabolic complications of peritoneal dialysis / Pennell P., Rojas C., Asif A., Rossini E. // Clin Nephrol. - 2004. - V. - 62 (1). - P. 35-43.
Phukan R. R. Unusual Dyslipidemia in Patients with Chronic Kidney Diseases / Phukan R. R., Goswami R. K. // Journal of Clinical and Diagnostic Research : JCDR. - 2017. - V. - 11(1). - P. BC01-BC04.
Protein Oxidative Stress and Dyslipidemia in Dialysis Patients / A. Marques de Mattos, L.Vieira Marino, P. Payäo Ovidio // Therapeutic Apheresis and Dialysis. - 2012. - V. - 16 (1). - P. 68-74.
Ronco C. Peritoneal Dialysis: From Basic Concepts to Clinical Excellence / Ronco C., Crepaldi С., Cruz Dinna N. / Karger Medical and Scientific Publishers. - 2009 - 328 c.
The versatility of HDL: A crucial anti-inflammatory regulator / Säemann M. D., Poglitsch M., Kopecky C., Haidinger M., [et al.] // Eur J Clin Invest. - 2010. - V. - 40. - P. 1131-1143.
Tsimihodimos V. Dyslipidemia associated with chronic kidney disease / Tsimihodimos V., Mitrogianni Z., Elisaf M. // Open Cardiovasc Med J. - 2011. - V. - 5. - P. 41-48.
Upadhyay R. K. Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders (Electronic resource) / Upadhyay R. K. // Journal of Lipids. - 2015 : 971453. - Mode of access : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407625/